First healthy volunteers dosed on schedule
Evgen Pharma PLC (AIM:EVG) SFX-01 licensing deal for up to $160.5m
SFX-01 licensing deal for up to $160.5m in milestone payments expands lead asset into neurodevelopmental disorders
AMTE Power PLC (AIM:AMTE) MoU with Cosworth to Supply UHP Cells
AMTE Power and Cosworth enter partnership to develop next-generation engines for electric vehicles
AMTE Power PLC selects Dundee, Scotland as preferred site for first MegaFactory as part of evolved execution strategy
AMTE Power Plc (“AMTE Power”, “AMTE” or the “Company”), the developer and manufacturer of lithium-ion and sodium-ion battery cells for specialist markets, is pleased to advise that the Board of
Evgen Pharma PLC (EVG.L) Progress with UK and US regulators for 2022 trials
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of cancers and inflammation, announces that it has progressed discussions with the
Evgen Pharma PLC (EVG.L) Publication of data in glioblastoma cells
Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells University of Auckland data
Evgen Pharma PLC (EVG.L) Early data for SFX-01 in leukaemia cell lines
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 was effective in
Evgen Pharma PLC (EVG.L) Progress with Glioma/Glioblastoma programme
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces further progress and an update on clinical trial plans for SFX-01 in glioblastoma (“GBM”).
Evgen Pharma PLC (EVG.L) SFX-01 to be evaluated in COVID-19 trial
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company, is delighted to announce participation in the recently notified funding initiative for COVID-19 clinical trials by the medical research
Evgen Pharma (EVG.L) Clinical trial that could reduce Covid-19 deaths
The University of Dundee is leading the clinical trial of a new anti-inflammatory drug it is hoped may reduce instances of severe lung damage and death in Covid-19 patients.